Bayer seeks approval of $2 billion plan to limit Roundup claims whbl.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from whbl.com Daily Mail and Mail on Sunday newspapers.
Appeals Court Rejects Bayer Appeal of $25M Roundup Cancer Verdict
A federal appeals court on Friday upheld a $25 million judgment and trial verdict finding Bayer’s Roundup caused a California resident’s non-Hodgkin lymphoma, dealing a blow to the chemical company’s hopes of limiting its legal risk over the weed-killer.
The 9th U.S. Circuit Court of Appeals in San Francisco rejected Bayer’s argument that lawsuits like Edwin Hardeman’s never should go to trial because federal pesticide laws barred allegations that the company failed to warn of Roundup’s cancer risks.
“It’s a slam dunk for plaintiffs,” said Leslie Brueckner, an attorney with Public Justice who helped with Hardeman’s appeal. “This proves these claims are viable in the tort system.”
Bayer And Plaintiffs Try Again To Settle Roundup Weed Killer Litigation
Bay City News Service
FacebookTwitterEmail
Bay City News Foundation
Bayer AG has reached a settlement to resolve many current and anticipated future claims against its agrochemical subsidiary Monsanto Company arising from its Roundup weed killer, alleged to cause non-Hodgkin lymphoma (NHL).
The settlement, announced Wednesday, was submitted to the U.S. District Court in San Francisco and is subject to approval of U.S. District Court Judge Vince Chhabria, who has presided over federal multi-district litigation involving hundreds of Roundup suits.
The settlement of the putative class action suit, if approved, will create a fund of up to $2 billion to be used to compensate class members over the next four years who have, or develop NHL, as a result of their exposure to Roundup herbicide. Compensation will be provided to qualifying class members at varying levels from $5,000 to $200,000.